Glofitamab alone or with other drugs for Richter's transformation
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called glofitamab, alone or combined with other drugs, for people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has changed into a faster-growing lymphoma (Richter's transformation). The goal is to see how well these treatments work and which combination might be best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has changed into a fast-growing lymphoma called diffuse large B-cell lymphoma (DLBCL). This is called Richter's transformation.
- You must be 18 years or older.
- You must be well enough to be up and about (ECOG performance status 0-2).
- You must have adequate organ function (like kidney, liver, and blood counts) that meets specific requirements for your treatment group.
- You must not have had certain prior treatments, such as specific types of immunotherapy or CAR T-cell therapy, within the past month.
- You must not have active cancers other than CLL or certain minor skin cancers, or any serious heart, lung, or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
This trial tests a new drug called glofitamab combined with standard chemo-immunotherapy (rituximab or obinutuzumab plus CHOP) for people with Richter syndrome, an aggressive lymphoma that arises from CLL. The goal is to see if the combination is safe and effective.
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.